Tirzepatide

Approved human use · product-specific labels.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Tirzepatide acts at both GIP and GLP-1 receptors, pathways involved in glucose regulation and appetite. Mounjaro and Zepbound contain the same molecule but have separate approved indications and product labels. [1]

02 Potential benefits

Mounjaro is FDA-approved to improve glycemic control in people with type 2 diabetes under its current label. Zepbound is FDA-approved under separate labeling for chronic weight management and obstructive sleep apnea in adults with obesity. Clinical evidence must be matched to the exact product, population, indication, and outcome studied. [1]

03 Evidence & its limits

The boxed warning concerns thyroid C-cell tumors observed in rats; whether tirzepatide causes these tumors in humans is unknown. Gastrointestinal reactions, contraindications, and other warnings require the exact product label. Approval does not extend automatically to unapproved copies or other uses. [1]

04 Risks & unknowns

Gastrointestinal adverse reactions are common and can be serious. Current labels include a boxed warning about thyroid C-cell tumors observed in rats; relevance to humans is unknown. Contraindications and additional warnings apply under the product-specific labeling. Approved products must be distinguished from unapproved or counterfeit copies. [1]

05 Status & scope

Mounjaro and Zepbound contain the same molecule but have separate approved indications and product labels. Approved products must be distinguished from unapproved or counterfeit copies. [1]

06 November 2026 safety update

FDA requires a warning about a potential increased risk of NAION, a rare optic-nerve condition that can cause permanent vision loss. Seek prompt medical attention for sudden painless vision loss or other visual changes. Individual labels may still be undergoing revision. [4]

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] FDA prescribing information: Mounjaro (revised January 2026)
[3] FDA prescribing information: Zepbound (revised February 2026)
[4] FDA / GLP-1 eye-safety notice / November 9, 2026

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.